logo
Share SHARE
FONT-SIZE Plus   Neg

Peregrine Cites Clinical Data To Highlight Potential Of Bavituximab

Clinical-stage biopharmaceutical company Peregrine Pharmaceuticals Inc (PPHM) Wednesday highlighted positive data from two Phase I investigator-sponsored trials and one preclinical study while evaluating the potential of bavituximab when combined with standard approved therapies in breast, liver and prostate cancers.

The company stated that in a Phase I trial of bavituximab with paclitaxel in five evaluable patients with HER-2 negative metastatic breast cancer, two patients achieved a complete tumor response, one achieved a partial response, and two had progressive disease according to Response Evaluation Criteria In Solid Tumors measurement criteria.

Additionally, the company presented data from a Phase I/II trial investigating bavituximab with sorafenib in patients with advanced hepatocellular carcinoma, in which no dose-limiting toxicities or serious adverse events were observed in the first phase of the trial.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply higher at the open, stocks continue to see notable strength in mid-day trading on Wednesday. Buying interest has waned from earlier in the session, however, leading the major averages to pull back well off their highs. Former Florida Gov. Jeb Bush and businessman Donald Trump top the list of Republican presidential candidates in a new CNN/ORC International poll, although both are well behind Hillary Clinton in potential general election matchups. Confusion refuses to die down in Europe even after crucial deadlines were missed and hapless Greeks stare into an uncertain future for their country, while other Europeans try to preserve the sanctity of the union and the euro.
comments powered by Disqus
Follow RTT